Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc CEO Armando Anido talks to Proactive about program updates for Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and developmental and epileptic encephalopathies.
In addition to the continued clinical development of its Zygel CBD gel in FXS, Anido said it plans to focus on the development of Zygel in ASD and 22q. Anido added that based on its research and strategic prioritization, the decision has been made to not move forward in DEE.